The source for the majority of short-and long-term complications associated with traditional 73 pacing systems can be attributed to the pocket and lead. Within months from the implant 74 procedure, as many as 1 in 8 patients may experience a complication such as infection, 75 hematoma, loose header connection, lead dislodgement, or pneumothorax.
1, 2 Chronically, 76 complications with traditional systems include infection, Twiddler's Syndrome, lead fracture and 77 insulation breach, venous thrombosis/obstruction, and tricuspid valve injury.
2 Advances in 78 battery chemistry and component design have enabled cardiac pacemakers to be dramatically 79 reduced in size and placed entirely in the heart, eliminating the need for a subcutaneous "pocket" 80 and a transvenous lead and the related complications. 81
To date, only the early performance of transcatheter pacing systems have been reported. successfully implanted by 94 physicians. Both the primary safety and efficacy objectives were 86 met at 6 months of follow-up. 4 In this report, we describe the long-term electrical performance 87 and safety objective of patients followed for up to 24 months from the Micra Transcatheter 88
Pacing Study. 89
Methods 90

Study Design 91
The design of the pivotal study has been described previously.
5 Briefly, the aim of the 92 prospective, non-randomized, worldwide clinical trial was to evaluate the short-term and long-93 term safety and efficacy of the Micra Transcatheter Pacemaker System. The protocol wasM A N U S C R I P T
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6 approved by the ethics committee at each of the 56 participating centers. Adverse events were 95 adjudicated by a Clinical Events Committee (CEC) comprised of independent physicians. Safety 96 oversight was provided by an independent data monitoring committee (DMC). 97
Patients and Procedures 98
Detailed inclusion/exclusion criteria have been previously described.
5 Enrolled patients met 99
Class I or II guideline recommendations 6, 7 for de novo ventricular pacing and were not restricted 100 by comorbidities. All patients provided written and informed consent. 101
The Micra transcatheter pacemaker is a single-chamber ventricular pacemaker, is 90% 102 smaller than a transvenous system, and is self-contained in a hermetically enclosed capsule (0.8 103 cubic centimeter, 2.0 grams). Functionality and features of the device are similar to existing 104 single chamber pacemakers and include rate adaptive pacing, remote monitoring capabilities, and 105 automated pacing capture threshold management to maximize battery longevity. Micra is 106 inherently MRI conditionally safe for full body scans in both 1.5 and 3.0 Tesla scanners due to 107 its small size and low amount of ferrous material. 8 
108
The device is implanted using a 23 French internal diameter/27 French outer diameter 109 introducer through a femoral vein and the delivery catheter is advanced into the right ventricle. 110
The device is fixated in the myocardium via 4 flexible nitinol tines. After verifying device 111 fixation and obtaining adequate electrical measurements, a tether is cut and the delivery system 112 is removed. 113
Enrolled patients underwent implant attempt and were followed, including adverse event 114
and device evaluation at 1, 3, and 6 months and then bi-annually for at least 12 months until all 115 successfully implanted patients had the opportunity to complete their 12-month visit at whichM A N U S C R I P T
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As reported previously, the two primary endpoints assessed the system's early performance: a 119 safety endpoint to evaluate freedom from major complications at 6 months and an efficacy 120 endpoint to evaluate the proportion of patients with low and stable pacing thresholds at 6 months. 121
Both primary objectives were met. 4 With respect to the safety objective, major complications 122 were defined as events resulting in death, permanent loss of device function due to mechanical or 123 electrical dysfunction, hospitalization, prolonged hospitalization by at least 48 hours, or system 124 revision. The diagnoses of all adverse events were reported by site investigators. An independent 125 CEC reviewed and adjudicated at minimum all procedure or system related events to determine 126 relatedness and seriousness. 127
The subject of this report is of the long-term safety and electrical performance. The trial 128 had a pre-specified long-term safety performance objective to be assessed after all implanted 129 patients had the opportunity to complete at least 12-months of follow-up. The objective was to 130 demonstrate that the freedom from major complications related to the Micra system or procedure 131 was significantly greater than 82% at 12 months post implant (assumed performance, 89%). For 132 a comparison of safety performance relative to conventional pacemaker systems with 133 transvenous leads, an individual patient level dataset of 2667 de novo pacemaker patients from 6 134 recent Medtronic trials of dual chamber pacing was assembled. 4 A single chamber dataset was 135 approximated by excluding events related only to the right atrial lead. Rates of major 136 complications (using the major complication criteria from the Micra trial) were compared 137 between Micra and the transvenous control group. Finally, electrical performance was assessed 138 in patients followed up to 24 months.
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Statistical Analysis 140
The study sample size of 720 patients successfully implanted with the Micra system provided 141 >90% power to test the study's two primary objectives.
4, 5 The long-term safety performance 142 goal of 82% was based on the major complication freedom rates at 12-months from the 6 trials in 143 the reference dataset and set to 1% below the 6-month performance goal used for the primary 144 objective to reflect the expectation that few major complications would be anticipated beyond 6-145 months post-implant. The 12-month Kaplan-Meier estimate of the freedom from major 146 complications was evaluated against the performance goal of 82% using a one-sample Wald test 147 implying that the long-term safety objective would be met if the lower two-sided 95% 148 confidence limit of the Kaplan-Meier estimate exceeded 82%. Simulation analyses confirmed the 149 power to test the long-term safety objective exceeded 90% when the 6-month major 150 complication freedom rate (primary objective) exceeded 90%. 151
The Fine-Gray 9 competing risk model was used to compare the risk of major 152 complication through 12-months between the 2667 patients in the transvenous control group and 153 the 726 Micra patients with an attempted implant. Similarly, this model was used to compare the 154 Micra patients and transvenous control group with respect to each component of the major 155 complication endpoint and within subgroups. Finally, the primary comparison was repeated with 156 a 1:1 propensity matched subgroup of transvenous control patients to adjust for differences in 157 patient characteristics, including age, sex, coronary artery disease history, congestive heart 158 failure history, atrial fibrillation history, hypertension history, valvular disease history, and all 159 pairwise interactions. All analyses were conducted with SAS software, version 9.4 (SAS 160 M A N U S C R I P T 4 (the original 6 month primary endpoints 171 report was on 725 attempted and 719 successfully implanted; one additional successful implant 172 occurred after database closure of the early performance analysis). Average follow-up duration 173 was 16.4 ± 4.9 months. Compliance to protocol-required study visits was >99%. 174
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Long-Term Safety 175
There were a total of 32 major complications in 29 patients adjudicated as related to the Micra 176 system or procedure. The long-term safety objective was met with 96.0% freedom from major 177 complications related to the Micra system or procedure at 12-months post-implant (95% CI: 178 94.2% -97.2%, P<0.0001 versus performance goal). Major complications are shown in Table 1 . 179
Four new major complications occurred since the primary results analysis, which occurred when 180 the first 300 patients had been followed for 6 months: 4 3 were associated with cardiac failure 181 events and 1 was associated with pacemaker syndrome. There were no radiographically visible 182 device dislodgements and no telemetry failures. Also, there were no infections related to theM A N U S C R I P T
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Of the 32 major complications, 24 (75%) occurred within 30 days of a Micra implant 185 attempt, and 6 (19%) occurred between 30 days and 6-months of implant attempt. Only two of 186 the major complications occurred after 6 months of the implant attempt. The two events 187 involving hospitalizations for heart failure at 300 and 343 days post implant, respectively, 188 occurred in two patients paced 87% and 99% of the time. programmed off to OOO mode), and 1 death following the procedure (Table 2) . 194
Of the 5 system revisions that met the criteria for a major complication, percutaneous 195 retrieval was attempted in 3 patients: 1 attempt was successful 16 days post implant, 1 attempt 196 was unsuccessful due to inability to extract the device 259 days post implant, and 1 attempt was 197 aborted due to fluoroscopy failure 229 days post implant. In the remaining 2 patients, the Micra 198 device was turned to Device Off mode without a retrieval attempt 32 and 44 days post implant. 199
Pacemaker Syndrome and Heart Failure 200
The 2 patients with a major complication related to pacemaker syndrome, as expected, were 201 among the 36% of patients who had no persistent atrial arrhythmias at baseline. Both patients 202
were upgraded -one to dual chamber pacing and one to CRT. 203
All 6 patients with a major complication related to heart failure had persistent atrial 204 arrhythmias at baseline. Only 1 of these patients was upgraded to CRT. The remainder were 205 managed with medication.
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Infections 207
There were no major infectious complications related to the Micra device or procedure. There 208 were 26 patients with 33 systemic infectious events during the trial; including septic shock (16), 209 endocarditis (2), bacteremia (3), and other septic events (12). In all instances, these events were 210 determined to be unrelated to the Micra device or procedure by the investigator, and these 211 determinations were confirmed by the CEC. Micra removal was not required in 25 of 26 patients. 212
In 1 patient, Micra was removed 430 days after implant during surgical replacement of an 213 infected prosthetic aortic valve. 214
Deaths 215
There were 77 deaths among the 745 enrolled subjects, 29 were previously reported 4 and there 216 were 48 new deaths since the primary results analysis. Of the 77 deaths, 10 were due to sudden 217 cardiac death, 22 were due to non-sudden cardiac death, 43 were due to non-cardiac death, and 2 218 were for unknown reasons. None of the deaths were considered related to the Micra system; 1 219 death was considered related to the implant procedure and was previously described. 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Across age, sex, and comorbidities, Micra was associated with a lower risk of major 230 complications through 12 months compared to transvenous pacemakers, and there were no 231 subgroups where Micra showed a higher risk (Figure 2) . 232
Electrical Performance 233
Of the 630 subjects with available pacing threshold data at 12 months, 93% had a pacing 234 threshold ≤1V (mean 0.60 ± 0.38V) at 0.24 ms pulse duration, and of the 58 subjects with 235 available pacing threshold data at 24 months, 97% had a pacing threshold ≤1V (mean 0.53 ± 236 0.23V) also at 0.24 ms. Pacing thresholds tended to decrease after implant and remained stable 237 thereafter ( Figure 3A) . The estimated battery longevity based upon use conditions at 12 months 238 was 12.1 years with 89% of patients having a projected longevity >10 years. The average pacing 239 impedance decreased from implant to 12-months (724 Ohms compared to 596 Ohms, Figure 3B of Micra avoided all of these complications. These data highlight that this advantage is observed 263 very early in follow-up and sustained in the longer-term. As with transvenous systems, the 264 majority of complications occurred early, but Micra patients experienced 82% fewer system 265 revisions and 47% fewer hospitalizations. These reductions were despite Micra patients being 266 older and having more co-morbidities than the transvenous control group patients. 267
While these long-term data demonstrate that the beneficial effects of Micra versus 268 transvenous systems are sustained to 2 years, we anticipate continued benefit chronically with 269
Micra. Long-term data suggest that transvenous systems remain prone to infections and are 270 associated with complications related to venous obstruction, lead fracture and insulation breach, 271 injury to the tricuspid valve, and Twiddler's Syndrome. Data of transcatheter pacemakers is 272 needed to shed light on the benefits of eliminating these chronic device complications. 273 M A N U S C R I P T
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14 to be >12 years which compares favorably to traditional systems.
11, 12 Given the typical patient 276 profile indicated for VVI pacing (e.g. average age 76 years, comorbidities), this longevity 277 projection suggests that a single Micra will serve the total pacing needs of at least 75% of 278 patients (Rys et al, unpublished data). Though experience was limited, Micra was able to be 279 retrieved percutaneously or turned off and left in place with a concomitant device placed, thus 280 allowing for options when device upgrade or replacement is required. 281
Although 36% of patients receiving Micra VVI pacing therapy were without persistent 282 atrial arrhythmia at baseline, only 1.1% of patients experienced major complications related to 283 this pacing mode -6 were associated with heart failure and 2 with pacemaker syndrome. While 284 careful pacing mode selection is advised, it appears that in this trial the low rate of heart failure 285
and pacemaker syndrome reflects reasonable use of this new technology. 286
Published literature indicates that cardiac implantable electronic device related infections 287 occur with traditional transvenous systems in 0.3-0.8% of implants. 13 Currently, experts 288 recommend complete hardware removal in virtually all of these situations as infections typically 289 involve the device pocket and/or the lead.
14, 15 Micra's small size, reduced surface area, and lack 290 of polymer insulated lead exposed to the bloodstream appear to substantially mitigate the risk of 291 early device infection. Over the long-term, these features will also promote complete device 292 encapsulation, which may significantly reduce the risk of chronic infection. The absence of 293 obvious device infections in this trial is encouraging. 294
Results from a differently designed leadless pacemaker (Nanostim, St. Jude Medical) 295 have also been reported. Primary efficacy and safety objectives were met in 300 patients, with 296 90% receiving adequate pacemaker function to 6 months. 3 In the total cohort of 526 patients, 297
device-related serious adverse events occurred in 6.5% of patients, including cardiac perforation analyses, as pre-specified, are restricted to the events meeting major complication criteria, and 305 events not leading to death, hospitalization, prolonged hospitalization by at least 48 hours, or loss 306 of device function are outside the scope of the present analysis. In addition, there are limited data 307 on system revisions, and no patients were followed beyond 2 years. Data from the Micra Post-308
Approval Registry (refer to https://clinicaltrials.gov/ct2/show/NCT02536118) is aimed to 309 address these questions. 310
Conclusion 311
The Micra Transcatheter Pacing Study met its prespecified long-term safety objective with 96% 312 freedom from major complications. Micra patients experienced a 48% reduction in the risk of 313 major complication at 12 months compared to transvenous patients from a historical control 314 group, resulting in 82% fewer system revisions and 47% fewer hospitalizations. Pacing 315 thresholds remained low and stable through 24 months follow-up. whom data were available at each study visit. 400
